Media stories about Kindred Biosciences (NASDAQ:KIN) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kindred Biosciences earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 44.8316434275542 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of KIN remained flat at $$8.45 during mid-day trading on Friday. The stock had a trading volume of 39,165 shares, compared to its average volume of 101,697. Kindred Biosciences has a 12-month low of $6.50 and a 12-month high of $9.80. The company has a market cap of $238.20, a PE ratio of -6.87 and a beta of 0.08.
Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). research analysts forecast that Kindred Biosciences will post -1.5 earnings per share for the current fiscal year.
In related news, insider Richard Chin sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $8.39, for a total value of $167,800.00. Following the transaction, the insider now directly owns 2,266,071 shares of the company’s stock, valued at approximately $19,012,335.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond Townsend sold 2,670 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $9.45, for a total value of $25,231.50. Following the completion of the transaction, the director now directly owns 25,057 shares in the company, valued at $236,788.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,761 shares of company stock worth $193,891. Insiders own 19.10% of the company’s stock.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.